In an attempt to improve outcomes for patients with acute myeloid leukemia (AML) after allogeneic hematopoietic cell transplantation (HCT), we conducted a Phase I/II study in which targeted irradiation delivered by 131 I-anti-CD45 antibody was combined with targeted busulfan (BU; area-undercurve, 600-900 ng/ml) and cyclophosphamide (CY; 120 mg/kg). Fifty-two of 59 patients (88%) receiving a trace 131 I-labeled dose of 0.5 mg/kg anti-CD45 murine antibody had higher estimated absorbed radiation in bone marrow and spleen than in any other organ. Forty-six patients were treated with 102-298 mCi 131 I
INTRODUCTION
Despite many advances in the field of hematopoietic cell transplantation (HCT), long-term disease-free survival for patients with acute myeloid leukemia (AML) in first remission undergoing HLAmatched related allogeneic transplantation has not exceeded 50-65% over the past two decades [1] [2] [3] [4] [5] [6] [7] .
Recurrent malignancy remains a major problem, particularly for patients with high-risk disease 3 . Efforts to decrease the risk of relapse after HLA-matched related HCT have included increasing the intensity of the preparative regimen. A prospective randomized study of different radiation doses in patients with AML in first remission undergoing matched sibling HCT suggested a substantial beneficial impact of whole-body radiation dose on relapse rates. In that study the relapse rate was 12% in patients receiving 15 .75 Gray (Gy) total body irradiation (TBI), compared to 35% following 12 Gy 8 . A similar study in
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From patients with chronic phase chronic myeloid leukemia (CML) found that the recurrence rate was 0% after 15 .75 Gy, compared with 25% after 12 Gy 9 . However, in both studies the higher TBI exposure was associated with significantly higher transplant-related mortality, such that there was no difference in longterm disease-free survival between the two randomized groups. The relatively steep dose-response curve of AML and CML for radiation demonstrated by these studies led to the hypothesis that if radiation could be better targeted directly to sites of leukemic involvement in bone marrow and spleen, while avoiding normal organs such as liver, lung, kidneys and mucous membranes, relapse rates might be decreased without excessive toxicity.
Radiolabeled monoclonal antibodies have been used in both preclinical [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and clinical [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] studies to deliver radiation to sites of leukemia or lymphoma. We selected CD45 as a target antigen because its expression is limited to myeloid and lymphoid cells, it is expressed by most AML samples at relatively high levels, approximately 200,000 copies per cell, and the antigen does not internalize after antibody binding 16 . Since CD45 is expressed on both normal and leukemic cells, it can be used to target marrow in both remission and relapse. Radioiodinated monoclonal antibodies reactive with the CD45
antigen have been demonstrated to deliver more radiation to bone marrow, spleen and lymph nodes than to normal non-target organs in murine and macaque studies 39, 40 .
In a previous Phase I study combining escalating doses of radiation delivered by 131 I-labeled anti-CD45 antibody with cyclophosphamide (CY) and 12 Gy TBI in patients with advanced acute leukemia and myelodysplastic syndrome, 84% of patients had favorable biodistribution of antibody (a higher estimated radiation-absorbed dose to marrow and spleen as compared to liver, lung and kidney) 29 . The estimated radiation doses delivered to marrow and spleen were 2.3-and 4.8-fold greater than to liver, the normal organ estimated to receive the highest dose in all but one patient. The maximum tolerated dose of radiation delivered by 131 I-anti-CD45 antibody was estimated to be 10.5 Gy to the liver when combined with CY/TBI.
Based on our demonstration that, in the majority of patients, greater estimated radiation doses could be delivered to marrow and spleen compared to liver, lung, and kidney, and that significant 
METHODS

Patient Selection
Between antibody produced and purified in the Biologics Production Facility at the FHCRC as previously described 29 . BC8 antibody was labeled with 131 I (New England Nuclear, Boston, MA, specific activity 8.0 Ci/mg) by the chloramine-T method and purified and tested as previously described 42 .
Determination of Antibody Biodistribution and Radiation Absorbed Dose
Patients first received an infusion of trace-131 I-labeled BC8 antibody to determine the biodistribution of antibody and estimate radiation absorbed doses to marrow, spleen, non-target organs, and the whole body delivered per millicurie (mCi) 131 I. Patient serum was tested for the presence of human anti-mouse antibody (HAMA) using an ELISA assay 42 . Organ volumes (liver, lungs, spleen and kidney) were calculated from chest and abdominal computed tomography 43 . Thyroid uptake of free Patients underwent quantitative gamma imaging at the end of infusion (hour 0) and then daily for three days using a dedicated GE MAXXUS, dual-headed, large-field-of-view camera with high-energy collimators ( Fig. 1) . Regions of interest including two marrow sites (right acetabulum and sacrum), spleen, liver, lungs, and kidneys were imaged using a 180° opposing view quantitative planar technique 43 .
Results were compared to an 131 I imaging standard for quantitation and were corrected for whole-body thickness attenuation and radioactive decay. A bone marrow biopsy was obtained the day after infusion (14 to 24 hours after the end of infusion), and weighed and counted against a weighed reference aliquot of 44, 45 . Time-activity curves were generated for each major source organ, marrow, and the whole body from the gamma camera region-of-interest images. The fractional timeactivity curves for each source organ were integrated to obtain source-organ residence times. Radiationabsorbed doses were then estimated using methods consistent with those recommended by the Society of Nuclear Medicine's special committee on Medical Internal Radiation Dose as previously described 46 .
Patient marrow volumes were normalized to the MIRD model values of 1120 grams for the standard 73 kg adult and 1050 grams for the 58 kg smaller adult woman, or 15-year-old, for dosimetry purposes.
Appropriate red marrow-to-marrow S values for the absorbed dose per unit-cumulated activity were used consistently for marrow dose calculations throughout the multi-year period of the study 45 .
A
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Therapy
Those patients for whom the biodistribution study estimated that a greater radiation-absorbed dose would be delivered to the marrow and spleen than to any normal organ were considered to have favorable biodistribution and were eligible to receive a therapy dose of 131 I-BC8. The therapy infusion of antibody was labeled with the amount of 131 I calculated to deliver the desired dose to the normal organ estimated to receive the highest radiation dose. The initial four patients were treated at Dose Level 1, with an estimated 3.5 Gy delivered to the normal organs by 131 I-BC8 antibody. The dose was then escalated to Grade IV, fatal) regimen-related toxicity, as defined by Bearman criteria, a scale developed specifically for marrow transplant patients 47 . Patients were prospectively evaluated for regimen-related toxicities daily for 30 days prior to dose escalation for subsequent patients. Escalation of the dose was to be allowed only if none of 10 patients treated at Dose Level 2 developed Grade III/IV regimen-related toxicity.
The therapy dose was administered on day -13 of the preparative regimen, which was 8 to 14
days after the biodistribution dose except for one patient with a 52-day interval. Patient serum was retested for HAMA the day prior to the therapy dose and if positive, the patient was off study and received an alternative HCT regimen. Patients remained in radiation isolation in lead-lined rooms after the therapy dose until radiation exposure was less than or equal to 2 mR/hour at 1 m (median 3 days). .
The radiolabeled antibody was infused through an automatic pump from a lead-shielded reservoir. Vital signs, as well as blood counts and blood chemistry analyses were performed daily by patients while they were in radiation isolation. Proximity of the nursing staff to the patient was limited except as needed for delivery of intravenous medications. Phenytoin was administered beginning day -8 and BU was started day -7. The first three patients received a total BU dose of 16 mg/kg adjusted ideal body weight administered as 1 mg/kg every 6 hours p.o. × 16 doses. To avoid excess toxicity, subsequent patients underwent pharmacokinetic monitoring of plasma BU levels with adjustment of BU dosing to maintain an average BU concentration of 600-900 ng/mL 48 . Patients then received CY 60 mg/kg i.v. on days -3 and -2, followed by infusion of unmanipulated bone marrow or peripheral blood stem cells (PBSC) on day 0.
Pharmacokinetic monitoring of CY was not performed on this study. Patients received cyclosporine (CSP) and methotrexate (MTX) for graft-versus-host disease (GVHD) prophylaxis. MTX was delivered at 15 mg/m 2 i.v. day 1 and 10 mg/m 2 on days 3, 6, and 11. CSP was delivered beginning on day -1 at 3 mg/kg/day i.v. in two divided doses or oral dosing as tolerated to achieve equivalent serum levels until day 50 followed by 5% taper per week through day 180 49 .
Statistical Analysis
Overall and disease-free survival were estimated using the method of Kaplan and Meier. Nonrelapse mortality (NRM) and relapse probabilities were computed using cumulative incidence estimates 50 .
Relapse was considered a competing risk for NRM, and death without relapse a competing risk for relapse. Cox regression was used to compare the hazard of mortality among patients entered on this antibody study to that among historical controls.
RESULTS
Patient Characteristics
Fifty-nine patients with AML in first remission received a biodistribution infusion of 131 I-BC8
antibody. Fifty-two (88%) patients (median age 41; range, 16 -55) receiving a biodistribution dose had favorable antibody biodistribution. All patients with unfavorable biodistribution of the radiolabeled antibody subsequently received HLA-matched related allogeneic transplants using standard BU/CY conditioning. Forty-six patients with a favorable biodistribution received a therapeutic dose of BC8 Ab labeled with an amount of 131 I estimated to deliver 3.5 Gy (first 4 patients) to 5.25 Gy (all subsequent patients) to the normal organ receiving the highest dose (Table 1) . Six patients with favorable biodistribution were not treated with a therapeutic dose of radiolabeled antibody because of donor problems in 2 patients, active fungal infection in 2 patients, relapse in 1 patient, and an elevated AST after biodistribution in 1 patient.
Patients were distributed across FAB classifications at diagnosis, with the exception that patients with acute promyelocytic leukemia were specifically not enrolled in the study ( Table 1 shows the characteristics of patients receiving 131 I-BC8/BU/CY conditioning prior to allogeneic HCT for AML in first complete remission. 
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In the first 26 patients, the estimated radiation dose delivered to lung was 1.8 ± 0.6 cGy/mCi, and in each patient the estimated lung dose was less than the liver dose. However, these estimates of lung dose were obtained by gamma camera images of lung obtained "through" ribs, and thus represent overestimates of lung dose because of 131 I in rib marrow. Because the liver is always the normal organ estimated to receive the highest dose, and because the actual dose delivered to lung is less than these estimates suggested, lung dose was not calculated in subsequent patients. For the 52 patients with a favorable biodistribution of 131 I-BC8 antibody, the average ratio of radiation delivered to marrow compared to the liver was 1.9, with ratios of 12.4 and 15.5 for marrow to kidney and to total body, respectively. For the 46 patients receiving a therapeutic dose, the ratio was 2.2 ± 0.5 for marrow to liver, 16.3 ± 3.3 for marrow to kidney, and 13.0 ± 3.1 for marrow to total body.
Therapy, Toxicities, and Engraftment
Forty-six patients received a therapy dose of 131 Eighteen (30%) patients reported nausea, and 5 (11%) emesis during the first days following the therapy dose of antibody, each complication presumably resulting from the radioiodine. All patients were discharged from radiation isolation by the fourth day after radiolabeled antibody treatment.
All patients developed at least Grade II mucositis (Bearman scale) after day zero, with onset typically occurring between days 1 to 3 post-HCT, and which required narcotic therapy. Three of the 46 patients (6.5%) developed Grade III/IV regimen related toxicities. Two patients treated at Dose Level 2 Table 3 . Acute GVHD in patients receiving 131 I-BC8/BU/CY and HLA-matched related allogeneic transplants for AML in first complete remission.
Organ Specific GVHD Severity Stage 59, 60 .
No acute GVHD 27 (57) 28 (61) 11 (24) 1 4 (9) 8 (17) 27 (59) 2 7 (15) 7 (15) 3 (7) 3 7 (15) 2 (4) 5 (11) 4 1 (2) 1 (2) 0 (0) 59, 60 . N (%) No acute GVHD I II III IV 9 (20) 4 (9) 20 (43) 12 (26) Nine patients died without disease recurrence and nine patients have relapsed as of last contact.
GVHD Grade
Eight of the nine relapsed patients had recurrence of their disease in the bone marrow, with one patient developing a skin chloroma. No correlation was found between the absorbed radiation dose delivered to the bone marrow or spleen and the risk of relapse. The absorbed radiation doses to the bone marrow and spleen were 11.3 Gy ± 3.3 and 28.4 Gy ± 4.4 for the patients who relapsed of their disease after transplant, respectively. For patients who did not relapse, the absorbed dose to bone marrow and spleen was 11.3 Gy ± 3.3 (p = .99) and 30.6 Gy ± 10.4 (p = .36), respectively. The estimate of NRM at 3 years is 21% (9-33%) and the estimated probability of relapse at this time is 19% (7-30%). The 3-year NRM in the group of patients with intermediate-risk cytogenetics is 21% (5-37%) and among the unfavorable
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Fig. 2:
Estimates of the probability of DFS, NRM, and relapse among all patients who received a therapeutic dose of 131 I-BC8 antibody, followed by BU/CY.
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Comparison of Overall Survival to Historical Control Patients
In order to gain an idea about the potential efficacy of this treatment, we compared overall survival between an antibody group and a group of control patients taken from the International Bone Marrow Transplant Registry (IBMTR). Given the strong correlation between cytogenetic risk and outcome, this comparison was restricted to patients whose cytogenetic risks were known. Furthermore, since only one antibody patient had favorable cytogenetics, the analysis was further confined to patients who had either intermediate-risk or unfavorable cytogenetics. For this "intent-to-treat" analysis, the antibody group contained 41 of the 46 patients who received a therapy dose of 131 I-BC8 antibody (the remaining 5 were missing cytogenetics), and 10 of the 13 patients who did not receive a therapy dose but went on to receive HCT without radiolabeled antibody. Three patients who did not receive a therapy dose
were not included in the comparison because one had unknown cytogenetics, one did not receive a transplant, and one had their transplant significantly delayed due to donor issues. The IBMTR patients were transplanted over a period of time comparable to the period that the Phase I/II trial currently reported was conducted, and this control group consisted of 509 patients. All IBMTR patients were transplanted for AML in first remission and conditioned with BU/CY alone. The IBMTR patients were, on average, younger (mean of 28 compared to a mean of 39), and a higher proportion had intermediaterisk cytogenetics compared to the antibody-treated patients (92% compared to 65%). After adjusting for these factors in addition to the presence of secondary AML (10% of antibody-treated patients had secondary AML compared to 4% of IBMTR patients), the hazard of mortality in the antibody group was 0.65 times that of the hazard in the group that received BU/CY alone (95% CI, 0.39 to 1.08; p=.09).
DISCUSSION
The use of 131 I-anti-CD45 antibody to deliver targeted radiation to bone marrow and spleen offers the opportunity to intensify the therapy received by leukemic cells to a greater extent than that received by the normal organs, which are the sites of dose-limiting toxicity. The results presented in this study 63 . Some additional toxicities, however, were clearly attributable to the radiolabeled antibody. The development of Grade II or greater mucositis was seen in all patients. Despite administration of Lugol's solution to all patients during both the biodistribution and therapy phases of radiolabeled antibody treatment, ~70% of patients developed elevated thyroid stimulating hormone levels.
All patients that developed hypothyroidism received exogenous thyroid supplementation. Whether these increased non-lethal toxicities due to the delivery of supplemental, targeted radiation to hematopoietic tissues by 131 I-anti-CD45 antibody will be balanced by the potential of a decreased risk of recurrent leukemia is unknown.
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The overall incidence of grades II -IV acute GVHD in this study was 71%. The apparent high rate of GVHD reported may be attributed to several factors. Most significantly, the reported incidence of grades II -IV acute GVHD after hematopoietic cell transplantation with HLA-identical sibling donors has increased considerably since the early 1990s at our Center 60 . The most striking change was an increased incidence of stage 1 gut GVHD involvement from 10% to 20% before 1992 to 50% to 60% since 1992, an increase almost certainly due to the aggressive use of endoscopy in patients with post-transplant anorexia. This increased incidence of grade II acute GVHD resulted in an overall incidence of grade II -IV acute GVHD of 60-70% for patients transplanted with standard conditioning regimens using sibling donors, which is consistent with the 71% incidence of grades II -IV acute GVHD in the current study.
While it remains possible that the radiolabeled antibody may contribute to the high incidence of acute GVHD, in the current study 59% of patients who received 131 I-BC8 antibody were graded to have stage 1 gut GVHD, suggesting that this high level of diagnostic scrutiny and increased surveillance at our Center may have led to the apparent high overall incidence of GVHD.
We have used 131 I as the radiolabel in our studies because there is extensive experience with its medical use, the technology for radiolabeling antibodies with iodine is well established, and its gamma component allows direct determination of labeled antibody biodistribution. Iodine-131 is a beta/gammaemitting radionuclide with a physical half-life of 8.1 days, a principal gamma ray energy of 364 keV, and a principal beta-particle spectrum with a maximum energy of 610 keV, an average energy of 190 keV, and a 90 th percentile range in tissue of 0.8 mm, which allows for kill of CD45 negative cells that are close to CD45 positive cells coated with labeled antibody 14 . However, the high-energy gamma component of 131 I requires that patients be treated in radiation isolation, and poses a radiation exposure risk for staff and family. We recently investigated if 90 Y, which does not emit characteristic gamma lines and does not require radiation isolation, might result in improved therapeutic ratios because of its higher energy and shorter half-life (2.7 days). We examined the relative organ localization and retention of 90 Y-anti-CD45
antibody in a non-human primate model, which has previously been useful for accurately predicting the biodistribution of radiolabeled anti-CD45 antibody in humans. These preliminary studies suggest that the . By targeting CD66, which is present on maturing myeloid cells, radiation is delivered to neighboring leukemia blasts, which are usually CD66 negative.
In an effort to gain preliminary evidence of the potential efficacy of the use of 131 I-anti-CD45
antibody, we performed a retrospective analysis comparing our data to registry data from the IBMTR on first remission AML patients conditioned with BU/CY alone prior to HCT. After adjusting for age and cytogenetics-risk, the hazard of mortality for the patients treated in our 131 I-BC8 antibody study is encouraging when compared to that among AML patients transplanted using a regimen of BU/CY alone.
Of course, such retrospective non-randomized comparisons have many weaknesses and cannot be used to definitively compare efficacy. The BU/CY regimens in the IBMTR control group were not limited to BU 16 mg/kg and CY 120 mg/kg, different forms of GVHD prophylaxis were used, as were different methods of supportive care. A carefully controlled randomized trial is necessary to definitively assess the use of 131 I-anti-CD45 antibody when combined with BU/CY as compared to the use of BU/CY alone.
However, the improved survival currently observed when compared to historical controls argues that such a study is, at least, reasonable.
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From In summary, the delivery of supplemental radiation doses to bone marrow and spleen by 131 I-anti-CD45 antibody is well tolerated when combined with BU/CY in patients undergoing HCT for AML in first remission. Although the use of radiolabeled antibody is labor-intensive, the encouraging results to date in patients treated with this preparative regimen supports continued study of this approach. A future Phase III randomized trial comparing 131 I-anti-CD45 antibody/BU/CY to BU/CY alone in this patient group will provide a definitive test of our hypothesis that the addition of 131 I-BC8 antibody to BU/CY will improve survival.
